A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer

LESSONS LEARNED: The combination of enobosarm and pembrolizumab was well tolerated and showed a modest clinical benefit rate of 25% at 16 weeks. Future trials investigating androgen receptor‐targeted therapy in combination with immune checkpoint inhibitors are warranted. BACKGROUND: Luminal androgen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncologist
Hauptverfasser: Yuan, Yuan, Lee, Jin Sun, Yost, Susan E., Frankel, Paul H., Ruel, Christopher, Egelston, Colt A., Guo, Weihua, Gillece, John D., Folkerts, Megan, Reining, Lauren, Highlander, Sarah K., Robinson, Kim, Padam, Simran, Martinez, Norma, Tang, Aileen, Schmolze, Daniel, Waisman, James, Sedrak, Mina, Lee, Peter P., Mortimer, Joanne
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons, Inc. 2020
Schlagworte:
Clinical Trial Results
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7873338/
https://ncbi.nlm.nih.gov/pubmed/33141975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13583
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge